DAWN H ROQUE
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family BEAUMONT, TX NPI 1003401480
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family TX Celgene Corporation All categories
General Payments — all program years on this page
$2,642.78
- Category: General Payments
- Program years: PY2021–2024
- Record count: 117
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,003.88 across 44 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,003.88 | 44 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $105.05 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $69.74 | 3 |
| Acerta Pharma LLC | $68.20 | 3 |
| ABBVIE INC. | $59.06 | 3 |
| Incyte Corporation | $54.28 | 3 |
| Rigel Pharmaceuticals, Inc. | $46.26 | 2 |
| EMD Serono, Inc. | $42.04 | 2 |
| Janssen Biotech, Inc. | $39.76 | 2 |
| PFIZER INC. | $39.07 | 2 |
| Ipsen Biopharmaceuticals, Inc | $37.42 | 2 |
| Genentech USA, Inc. | $37.14 | 2 |
| Regeneron Healthcare Solutions, Inc. | $33.89 | 1 |
| Pharmacosmos Therapeutics Inc. | $33.34 | 1 |
| PharmaEssentia USA Corporation | $32.35 | 1 |
| EISAI INC. | $32.01 | 1 |
| Daiichi Sankyo Inc. | $29.82 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $27.30 | 1 |
| Blueprint Medicines Corporation | $25.87 | 1 |
| Merck Sharp & Dohme Corporation | $24.96 | 1 |
| Deciphera Pharmaceuticals Inc. | $24.05 | 1 |
| Karyopharm Therapeutics Inc. | $23.23 | 1 |
| SOBI, INC | $22.52 | 1 |
| BeiGene USA, Inc. | $22.06 | 1 |
| GlaxoSmithKline, LLC. | $21.37 | 1 |
| Azurity Pharmaceuticals, Inc. | $19.11 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.02 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $15.96 | 1 |
By program year
Records — PY2024 (44)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.